- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03467880
Multicenter Study of Impulse Oscillometry in Chinese
March 10, 2018 updated by: Jinping Zheng, Guangzhou Institute of Respiratory Disease
The purpose of this study is to establish the reference values of impulse oscillometry (IOS) in healthy Chinese, and compare the indices of IOS in patients with lung disease, such as chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease (ILD), and upper airway Obstruction (UAO).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
4000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100005
- Recruiting
- Beijing Hospital
-
Contact:
- Yimeng Yang
- Phone Number: +86 13911738389
- Email: d860@sina.com
-
Principal Investigator:
- Tieying Sun
-
Sub-Investigator:
- Yimeng Yang
-
Guangzhou, China, 510120
- Not yet recruiting
- State Key Laboratory of Respiratory Disease,China Clinical Research Center of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University
-
Contact:
- Jinping Zheng, MD
- Phone Number: +86-20-83062729
- Email: jpzhenggy@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 95 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Subjects will be recruited from outpatient clinics.
Description
Inclusion Criteria for healthy subjects:
- life-long non-smokers
- no symptoms and history of chronic cardiopulmonary diseases (chronic bronchitis, asthma, lung cancer, pulmonary fibrosis, pulmonary tuberculosis, chronic heart diseases, etc.)
- no abnormal findings on physical examination
- written informed consent was obtained
Inclusion Criteria for COPD:
- Diagnosis of chronic obstructive pulmonary disease (COPD), as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines and post-bronchodilator FEV1/FVC (forced vital capacity) < 70%.
Inclusion Criteria for asthma:
- Diagnosis of asthma, as classified by national and international asthma guidelines.
Inclusion Criteria for ILD:
- ILD diagnosis confirmed by lung biopsy, X ray or BALF analysis.
Inclusion Criteria for UAO:
- Diagnosis of UAO.
Exclusion Criteria for healthy subjects:
- upper or lower respiratory infection within 4 weeks
- long-term exposure to harmful gas or particles
- using β-blocker for treatment
- pregnant women, epileptic
- other diseases or surgeries potentially affecting lung function
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Healthy subjects
Healthy subjects.
|
No treatment given but observation with IOS
|
|
Chronic obstructive pulmonary disease
Patience with chronic obstructive pulmonary disease.
|
No treatment given but observation with IOS
|
|
Asthma
Patience with asthma.
|
No treatment given but observation with IOS
|
|
Interstitial lung disease
Patience with interstitial lung disease.
|
No treatment given but observation with IOS
|
|
Upper airway obstruction
Patience with upper airway obstruction.
|
No treatment given but observation with IOS
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Airway resistance
Time Frame: one minute
|
The indices of Airway resistance include total respiratory impedance (Zrs).
|
one minute
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC, and maximum midexpiratory flow (MMEF).
Time Frame: one minute
|
The indices of spirometry include forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC, and maximum midexpiratory flow (MMEF).
|
one minute
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: Jinping Zheng, MD, State Key Laboratory of Respiratory Disease,China Clinical Research Center of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2016
Primary Completion (Anticipated)
June 1, 2018
Study Completion (Anticipated)
December 1, 2018
Study Registration Dates
First Submitted
February 14, 2018
First Submitted That Met QC Criteria
March 10, 2018
First Posted (Actual)
March 16, 2018
Study Record Updates
Last Update Posted (Actual)
March 16, 2018
Last Update Submitted That Met QC Criteria
March 10, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GIRD201536
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
University of LeicesterUniversity Hospitals, Leicester; University of StrathclydeRecruitingChronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway DiseaseUnited Kingdom
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Clinical Observation
-
Escola de Saúde Pública do CearáUnknown
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedMalignant Neoplasm | Side EffectUnited States
-
Escola de Saúde Pública do CearáRecruiting
-
Koç UniversityRecruitingComplication,Postoperative | Indication, UnlabeledTurkey
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Active, not recruitingStage III Vulvar Cancer | Vulvar Squamous Cell Carcinoma | Stage I Vulvar Cancer | Stage II Vulvar CancerUnited States, Canada
-
Children's Cancer and Leukaemia GroupUnknownNeuroblastoma | Long-term Effects Secondary to Cancer Therapy in Children
-
Northwell HealthNot yet recruitingObstructive Sleep Apnea | Normal Tension GlaucomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Terminated
-
University of CalgarySunnybrook Health Sciences Centre; CHU de Quebec-Universite Laval; Université... and other collaboratorsCompletedPneumothoraxCanada